Concepedia

Suresh Durgam

SD

Statistics

Publications

45

Citations

3.5K

H-Index

33

Active since

2005

Affiliations

Allergan (United States)(Current)

Gedeon Richter (Hungary)

Prescott College

Forest Research Institute

Intra Cellular Therapies (United States)

Suresh Durgam is an author at Allergan (United States) specializing in psychopharmacology, psychiatry, and medicine.

ORCID

Publications per year

2005–2025

45

Publications

45

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

György Németh, I. Laszlovszky, Pál Czobor et al. · The Lancet · 2017 · 352 citations

, , +14

An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression

Suresh Durgam, Willie Earley, Alan Lipschitz et al. · American Journal of Psychiatry · 2015 · 206 citations · Full text

, , +17

Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials

Eduard Vieta, Suresh Durgam, Kaifeng Lu et al. · European Neuropsychopharmacology · 2015 · 192 citations · Full text

, , +17

An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial

Suresh Durgam, Anju Starace, Dayong Li et al. · Schizophrenia Research · 2014 · 192 citations · Full text

, , +17

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder

Eduard Vieta, Willie Earley, Maria Victoria Burgess et al. · International Clinical Psychopharmacology · 2018 · 190 citations · Full text

, , +16

1–5 of 45